For decades, microbial fermentation has been used for the commercialization of biologics, with the fermentation of recombinant proteins such as insulin in stainless steel bioreactors as large as 100,000 L. A long-standing favorite within the industry, these stainless-steel fermenters boast a long history in biopharma manufacturing — though are not without their limitations.
Recent innovations in single-use fermenters, which offer an agile and cost-effective solution with reduced cleaning and validation requirements, have led single-use fermenters to gain ground quickly — but knowing when to use stainless steel versus single-use fermenters, or even a hybrid approach, can be challenging.
Join this webinar as the featured speakers discuss the pros, cons and use cases for each type of technology and what the speakers think the future holds when it comes to their sustainability within the industry. The speakers will also share things to consider when looking for a contract development and manufacturing organization (CDMO) to partner with for fermentation needs.
Gregor Awang, Director, Biologics Process Development, BIOVECTRA
A process development leader with an extensive track record of developing upstream and recombinant-protein downstream processes and tech transferring these processes from lab to manufacturing scale, Gregor Awang, PhD, has 25+ years of expertise in developing microbial and mammalian processes in biopharma. He has served as BIOVECTRA’s Director, Process Science & Development Services-Biologics since 2019. Dr. Awang has worked with academic collaborators to develop recombinant processes and served on the Board of Directors of Mabnet, a Canadian academic/government consortium to train SMEs in mAb production within Canada.Message Presenter
Cameron Graham, Pharmaceutical Process Engineer, BIOVECTRA
Cameron Graham, P.Eng., Pharmaceutical Process Engineer, BIOVECTRA, offers nearly a decade’s worth of experience in chemical engineering, with the last five years concentrated specifically on the bio-pharmaceutical industry. In his current role at BIOVECTRA, Cameron develops upstream biologics technologies and fermentation scale up strategy, from lab to industrial scale. Cameron graduated from Dalhousie University with a degree in Chemical Engineering.Message Presenter
Brady Cole, Vice President Equipment Solutions, ABEC
Brady Cole has over 25 years of technical and commercial experience in high technology industries. He began his career developing plasma deposition and etch processes for advanced microelectronics. He later moved on to product management roles in the semiconductor capital equipment industry at Mattson Technology and MKS Instruments. Since joining ABEC in 2002, Brady has held leadership positions in product management, applications, and sales. He currently oversees ABEC’s Product function, including product development and product management.Message Presenter
Who Should Attend?
This webinar will appeal to mid/senior-level professionals from pharmaceutical and biotechnology companies and research/academic institutions.
- Biochemistry and Molecular Biology
- Chemistry/Professional Chemistry/Medicinal Chemistry
- Analytical Chemistry
- API Manufacturing
- Chemical and Biochemical Engineering
- Manufacturing Engineering
- Processes Safety Scientists
- Chief Scientific Officers
- Research Scientists
What You Will Learn
Attendees of this webinar will:
- Understand the benefits and constraints of both stainless steel and single-use bioreactors
- Learn more about the use cases for different types of fermenters
- Understand areas of consideration regarding partnering with a contract development and manufacturing company (CDMO)
BIOVECTRA is a global biotech and pharmaceutical CDMO that specializes in clinical-to-commercial scale production capabilities for: biologics, bioreagents, fermented small molecules, synthetic small molecules, and active pharmaceutical ingredients. Flexibility, creativity, process optimization and compliance are at the heart of our method. With more than 50 years of experience, 550+ employees, and cGMP facilities in Prince Edward Island and Nova Scotia, Canada we assure our programs advance on time and with the highest quality outcomes.